Patent ID: 6350746
Filing Date: 2002-02-26
Classification: A61P,C07C,C07D

Abstract:
A compound selected from the group consisting of the following formulae: wherein:A is â€”N&boxH;; Z1 is â€”Oâ€”, â€”N(R8)â€”, â€”Sâ€”, or â€”CH2Oâ€”; Z2 is â€”Oâ€”, â€”N(R8)â€”, â€”Sâ€”, or â€”OCH2â€”; R1 and R3 are independently hydrogen, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, nitro, â€”N(R8)R9, â€”C(O)OR8, â€”C(O)N(R8)R9, â€”C(O)N(R8)CH2C(O)N(R8)R9, â€”N(R8)C(O)N(R8)R9, â€”N(R8)C(O)R8, â€”N(R8)S(O)2R8, or â€”N(R8)C(O)N(R8)CH2C(O)N(R8)R9; R2 is hydrogen; halo; alkyl; haloalkoxy; â€”OR8; â€”C(O)OR8; â€”C(O)N(R8)R9; â€”N(R8)R9; â€”C(O)N(R8)(CH2)mC(O)OR8 (where m is 0 to 3); â€”N(R8)(CH2)nC(O)OR8 (where n is 1 to 3); â€”N((CH2)nN(R8)R9)(CH2)nC(O)OR8 (where each n is 1 to 3); â€”O(CH2)nC(O)N(R8)R9 (where n is 1 to 3); â€”O(CH2)pC(O)OR8 (where p is 1 to 6); â€”N(R8)(CH2)nC(O)N(R8)(CH2)nC(O)OR8 (where each n is independently 1 to 3); 4-morpholinyl; 3-tetrahydrofuranoxy; or R2 is aryloxy (optionally substituted by one or more substituents independently selected from the group consisting of â€”OR8, â€”C(O)N(R8)R9, halo, alkyl, carboxy, alkoxycarbonyl, haloalkoxy, haloalkoxycarbonyl, alkoxycarbonylalkyl, carboxyalkyl, aminocarbonylalkyl, (alkylamino)carbonylalkyl, (dialkylamino)carbonylalkyl, (arylamino)carbonylalkyl, (aralkylamino)carbonylalkyl, alkoxycarbonylalkenyl, carboxyalkenyl, aminocarbonylalkenyl, (alkylamino)carbonylalkenyl, (dialkylamino)carbonylalkenyl, (arylamino)carbonylalkenyl, (aralkylamino)carbonylalkenyl, (hydroxyalkoxy)carbonyl, (alkoxy)alkoxycarboxyl, (hydroxyalkoxy)alkoxycarboxyl, ((alkoxy)alkoxy)alkoxycarboxyl, tetrazolyl, morpholin-4-ylalkyl, and (1,2)-imidazolinyl (optionally substituted by alkyl)); or R2 is 1-piperazinyl (optionally substituted by one or more substituents independently selected from the group consisting of alkyl, carboxy, carboxyalkyl, alkoxycarbonyl, and alkoxycarbonylalkyl); or R2 is 1-piperazinoyl (optionally substituted by one or more substituents selected from the group consisting of alkyl, carboxy, carboxyalkyl, alkoxycarboxyl, and alkoxycaboxylalkyl); or R2 is 1-piperidinyl (optionally substituted by one or more substituents selected from the group consisting of carboxy, carboxyalkyl, alkoxycarbonyl, and alkoxycarbonylalkyl); or R2 is (3,4)-piperidinyloxy (optionally substituted by one or more substituents selected from the group consisting of alkylcarbonyl, carboxy, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, and tetrazolylalkyl); or R2 is piperidin-4-ylamino (wherein the amino is optionally substituted by alkyl and the piperidinyl group is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl and aralkyl); or R2 is 3-pyrrolidinyloxy (optionally substituted by one or more substituents selected from the group consisting of alkyl, aralkyl, amidino, 1-iminoethyl, carboxy, carboxyalkyl, alkoxycarbonyl and alkoxycarbonylalkyl); R4 and R7 are independently hydrogen, halo, alkyl, nitro, â€”OR8, â€”C(O)OR8, â€”C(O)N(R8)R9, â€”N(R8)R9, â€”N(H)C(O)R8, or â€”N(H)S(O)2R8; R5 is â€”C(NH)NH2, â€”C(NH)NHOR8, â€”C(NH)N(H)C(O)OR8, or â€”C(NH)N(H)C(O)R8; R6 is halo, alkyl, haloalkyl, haloalkoxy, nitro, amino, ureido, guanidino, â€”OR8, â€”C(NH)NH2, â€”C(NH)NHOH, â€”C(O)R10, â€”(CH2)mC(O)N(R8)R9 (where m is 0 to 3), â€”CH(OH)C(O)N(R8)R9, â€”(CH2)mN(R8)R9 (where m is 0 to 3), â€”(CH2)mC(O)OR8 (where m is 0 to 3), â€”N(H)C(O)R8, or (1,2)-tetrahydropyrimidinyl (optionally substituted by alkyl); each R8 and R9 are independently hydrogen, alkyl, aryl, or aralkyl; and R10 is hydrogen, alkyl, aryl, aralkyl, 1-pyrrolidinyl, 4-morpholinyl, 4-piperazinyl, 4-(N-methyl)piperazinyl, or 1-piperidinyl; or a pharnaceutically acceptable salt thereof.